Advertisement

Radiotherapy and Third Generation Concurrent Chemotherapy Agents

  • Ross Bland
  • Puneeth Iyengar
  • Hak Choy
Chapter
Part of the Medical Radiology book series (MEDRAD)

Abstract

Evidence shows that treating locally advanced non-small cell lung cancer (NSCLC) patients with concurrent radiation and second generation chemotherapy agents provides a survival benefit when compared to delivering the same therapy sequentially. However, survival results remain dismal and concurrent chemoradiation exhibits significant toxicity. As third generation chemotherapy agents have become available, their radiation-sensitizing properties have been extensively studied in the laboratory. Subsequently, clinical studies have been performed to evaluate the potential benefit of incorporating these newer agents in concurrent chemoradiation regimens. This chapter aims to provide insight into how these agents were transitioned from the laboratory bench to their current role in the standard of care of patients with locally advanced disease.

Keywords

Median Survival Time Advanced NSCLC Radiation Therapy Oncology Group Generation Agent Radiation Pneumonitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abratt RP, Bezwoda WR, Falkson G et al (1994) Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 12:1535–1540PubMedGoogle Scholar
  2. Akerley W, Herndon JE Jr, Lyss AP, Choy H, Turrisi A, Graziano S, Williams T, Zhang C, Vokes EE, Green MR (2005) Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study–CALGB 9534. Clin Lung Cancer 7(1):47–53PubMedCrossRefGoogle Scholar
  3. Albain KS, Crowley JJ, Turrisi AT et al (2002) Concurrent cisplatin, etoposide plus radiotherapy for pathologic stage IIIB non-small cell lung cancer: A Southwest Oncology Group phase II study (S9019). J Clin Oncol 20:3454–3460PubMedCrossRefGoogle Scholar
  4. Amorino GP, Hamilton VM, Choy H (1999) Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitro. Radiat Oncol Investig 7(6):343–352PubMedCrossRefGoogle Scholar
  5. Andoh T, Ishii K, Suzuki Y et al (1987) Characterization of a mammalian mutant with a camptothecin-resistant DNA topoisomerase I. Proc Natl Acad Sci USA 84:5565–5569PubMedCrossRefGoogle Scholar
  6. Auperin A, Rolland E, Curran WJ et al., on behalf on the NSCLC Collaborative Group (2007) Concomitant radio−chemotherapy (RT−CT) versus sequential RT−CT in locally advanced non-small cell lung cancer (NSCLC). A meta-analysis using individual patient data from randomised clinical trials. J Thorac Oncol 2(8 suppl 4):S310Google Scholar
  7. Begg AC, VaderKolk PJ, Edmondt J et al (1987) Radiosensitization in vitro by cis-diammine (1, 1 -cyclobutanedicarboxyalto) platinum(II) (carboplatin, JM8) and etylnediammine malnatoplatinum(II) (JM40). Radiat Oncol 9:157–165CrossRefGoogle Scholar
  8. Begg AC, Stewart FA, Dewitt L et al (1989) Interaction between cisplatin and radiation in experimental rodent tumors and normal tissues. In: Hill B, Bellamy A (eds) Antitumor Drug Radiation Interactions. CRC Press, Boca Raton, FL, pp 154–510Google Scholar
  9. Belani CP (1993) Multimodality management of regionally advanced non-small-cell lung cancer. Semin Oncol 20:302–314PubMedGoogle Scholar
  10. Belani CP, Aisner J, Day R et al (1997) Weekly paclitaxel and carboplatin with simultaneous thoracic radiotherapy for locally advanced non-small cell lung cancer: Three year follow-up. Proc Am Soc Clin Oncol 16:448a (abstr 1608)Google Scholar
  11. Belani CP, Choy H, Bonomi P et al (2005) Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multimodality protocol. J Clin Oncol 23:5883–5891PubMedCrossRefGoogle Scholar
  12. Bischof M, Weber KJ, Blatter J, Wannenmacher M, Latz D (2002) Interaction of pemetrexed disodium (ALIMTA, multitargeted antifolate) and irradiation in vitro. Int J Radiat Oncol Biol Phys 52:1381–1388PubMedCrossRefGoogle Scholar
  13. Bischof M, Herfarth K, Thomas M et al (2010) Phase 1/2 study of pemetrexed in combination with carboplatin and concomitant thoracic radiotherapy in chemonaϊve patients with inoperable Stage I-IIIb non-small cell lung cancer: a single-arm, open-label, monocentric phase 1/2 study. Deutsche Gesellschaft fur Hamatologie und Onkologie (abstract)Google Scholar
  14. Blackstock AW, Lesser GJ, Fletcher-Steede J et al (2001) Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 51:1281–1289PubMedCrossRefGoogle Scholar
  15. Blackstock AW, Ho C, Butler J et al (2006) Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer. J Thorac Oncol 1:434–440PubMedCrossRefGoogle Scholar
  16. Blagosklonny M, Schulte TW, Nguyen P et al (1996) Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-1 and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 56:1851–1854PubMedGoogle Scholar
  17. Blanco R, Solé J, Montesinos J, Mesía C, Algara M, Terrassa J, Gay M, Domenech M, Bastus R, Bover I, Nogué M, Vadell C, ACROSS (2008) Induction chemotherapy with cisplatin and gemcitabine followed by concurrent chemoradiation with twice-weekly gemcitabine in unresectable stage III non-small cell lung cancer: final results of a phase II study. Lung Cancer 62(1):62–71PubMedCrossRefGoogle Scholar
  18. Bonomi P, Kim K, Fairclough D et al (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18:623–631PubMedGoogle Scholar
  19. Brade AM (2010) A phase II study of concurrent pemetrexed/cisplatin/radiation (RT) for unresectable stage IIIA/b non small cell lung cancer (NSCLC) [abstract 7087]. J Clin Oncol 28:s15Google Scholar
  20. Brade A, Bezjak A, MacRae R, Laurie S, Sun A, Cho J, Leighl N, Pearson S, Southwood B, Wang L, McGill S, Iscoe N, Shepherd FA (2011) Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 79(5):1395–1401PubMedCrossRefGoogle Scholar
  21. Bradley J, Bae K, Graham M et al (2010) Primary analysis of the phase II component of a phase I/II dose intensification study using three-dimensional conformal radiation therapy and concurrent chemotherapy for patients with inoperable non-small cell lung cancer: RTOG 0117. J Clin Oncol 28:2475–2480PubMedCrossRefGoogle Scholar
  22. Bunn PA Jr, Kelly K (1995) A phase I study of carboplatin and paclitaxel in non-small-cell lung cancer: a university of colorado cancer center study. Semin Oncol 22(suppl 9):2–6PubMedGoogle Scholar
  23. Bunn PA Jr, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4:1087–1100PubMedGoogle Scholar
  24. Calabro-Jones PM, Fahey RC, Smoluk GD et al (1985) Alkaline phosphatase promotes radioprotection and accumulation of WR-1065 in V79–171 cells incubated in medium containing WR-27821. Int J Radiat Oncol Biol Phys 47:23–27Google Scholar
  25. Cardenal F, Arnaiz M, Moran T et al (2009) Concurrent chemoradiation with pemetrexed and cisplatin followed by consolidation pemetrexed for patients with unresectable stage III NSCLC: preliminary results of a phase I study. IASLC 13th World Conference on Lung Cancer:P3.0007 (abstract)Google Scholar
  26. Casas F, Viñolas N, Ferrer F, Agustí C, Sanchez M, Maria Gimferrer J, Lomeña F, Campayo M, Jeremic B (2011) Long-term results of a phase II trial of induction paclitaxel-carboplatin followed by concurrent radiation therapy and weekly paclitaxel and consolidation paclitaxel-carboplatin in stage III non-small cell lung cancer. J Thorac Oncol 6(1):79–85PubMedCrossRefGoogle Scholar
  27. Chakravarthy A, Choy H, Devore RF III et al (2000) Phase I trial of outpatient fweekly irinotecan (CPT-11) and carboplatin with concurrent radiation therapy for stage III unresectable non-small cell lung cancer: a Vanderbilt Cancer Center affiliate network (VCCAN) trial. Proc Am Soc Clin Oncol 18:1–2040Google Scholar
  28. Chen AY, Okunieff P, Pommier Y et al (1997) Mammalian DNA topoisomerase I mediates the enhancement of radiation cytotoxicity by camptothecin derivatives. Cancer Res 57:1529–1536PubMedGoogle Scholar
  29. Choy H Schwartzberg L, Dakhil S et al (2010) Ongoing phase II study of pemetrexed plus carboplatin or cisplatin with concurrent radiation therapy followed by pemetrexed consolidation in patients with favorable-prognosis inoperable stage IIIA/B non-small-cell lung cancer: interim update.J Clin Oncol 2010 ASCO Annual Meeting Procededings 28 (suppl 15):7082(abstract)Google Scholar
  30. Choy H, Devore RF 3rd, Hande KR, Porter LL, Rosenblatt P, Yunus F, Schlabach L, Smith C, Shyr Y, Johnson DH (2000) A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 47(4):931–937PubMedCrossRefGoogle Scholar
  31. Choy H, Jain AK, Moughan J, Curran W, Whipple G, Demas WF, Ettinger DS (2009) RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy (“ping-pong trial”) followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thorac Oncol 4(1):80–86PubMedCrossRefGoogle Scholar
  32. Choy H, Safran H (1995) Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Semin Oncol 22(suppl 9):55–57PubMedGoogle Scholar
  33. Choy H, Rodriguez FF, Koester S et al (1993) Investigation of Taxol as a potential radiation sensitizer. Cancer 71:3774–3778PubMedCrossRefGoogle Scholar
  34. Choy H, Akerley W, Safran H et al (1994) Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12(12):2682–2686PubMedGoogle Scholar
  35. Choy H, Akerley W, Safran H et al (1998) Multi-institutional phase II trial of paclitaxel, carboplatin and concurrent radiation therapy for locally advanced inoperable non-small cell lung cancer. J Clin Oncol 16:3316–3322PubMedGoogle Scholar
  36. Choy H, DeVore RF, Hande KR, Porter LL, Rosenblatt PA, Slovis B, LaPorte K, Shyr Y, Johnson DH (2001) Phase I trial of outpatient weekly docetaxel, carboplatin, concurrent thoracic radiation therapy for stage III unresectable non-small cell lung cancer. Lung Cancer 34(3):441–449PubMedCrossRefGoogle Scholar
  37. Choy H, Jain AK, Moughan J, Curran W, Whipple G, Demas WF, Ettinger DS (2009) RTOG 0017: a phase I trial of concurrent gemcitabine/carboplatin or gemcitabine/paclitaxel and radiation therapy (“Ping-Pong Trial”) followed by adjuvant chemotherapy for patients with favorable prognosis inoperable stage IIIA/B non-small cell lung cancer. J Thoracic Oncol 4(1):80–86CrossRefGoogle Scholar
  38. Ciuleanu TE, Brodowicz T, Belani CP et al (2008) Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol 26(suppl 15):426s (Abstract 8011)Google Scholar
  39. Clark JW, Santos-Moore AS, Choy H (1998) Sequencing of taxol and carboplatinum therapy. Submitted 1995 AACR Annual Meeting 36:298Google Scholar
  40. Clarke S, Boyer M, Millward M et al (1997) Phase II study of LY231514, a multi-targeted antifolate, in patients with advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 16:465a (abstr 1670)Google Scholar
  41. Coughlin CT, Richmond RC (1989) Biologic and clinical developments of cisplatin combined with radiation: Concepts, utility, projections of new trials, and the emergence of carboplatin. Semin Oncol 16(suppl 6):31–43PubMedGoogle Scholar
  42. Crawford J, O’Rourke M, Schiller JH, Spiridonidis CH, Yanovich S, Ozer H, Langleben A, Hutchins L, Koletsky A, Clamon G, Burman S, White R, Hohneker J (1996) Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small cell lung cancer. J Clin Oncol 14:2777–2784Google Scholar
  43. Cros S, Wright M, Roussakis C et al (1989) Experimental antitumor activity of navelbine (5’-nor-anhydrovinblastine, vinorelbine). Semin Oncol 16(Suppl 4):15–20PubMedGoogle Scholar
  44. Curran WJ, Scott CB, Langer CJ et al (2003) Longterm benefit is observed in a phase III comparison of sequential versus concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410. Proc Am Soc Clin Oncol 22:621 (suppl; abstr 2499)Google Scholar
  45. Davies AM, Chansky K, Lau DH, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR, SWOG S9712 (2006) Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol. 24(33):5242–5246PubMedCrossRefGoogle Scholar
  46. Dillman RO, Seagren SL, Propert KJ et al (1990) A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 323:940–945PubMedCrossRefGoogle Scholar
  47. Dillman RO, Herndon J, Seagren SL et al (1996) Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of Cancer and Leukemia Group B (CALGB) S433 trial. J Natl Cancer Inst 88:1210–1215PubMedCrossRefGoogle Scholar
  48. Divers SG, Spencer SA, Carey D, Busby EM, Hyatt MD, Robert F (2005) Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer. J Clin Oncol 23(27):6664–6673PubMedCrossRefGoogle Scholar
  49. Douple EB (1993) Platinum chemotherapy for cancer treatment. In: Brooks RR (ed) Noble Metals and Biological Systems. CRC Press, Boca Raton, FL, pp 349–376Google Scholar
  50. Edelstein MP, Wolfe LA III (1996) Duch DS: potentiation of radiation therapy by vinorelbine (Navelbine) in non-small cell lung cancer. Semin Oncol 23:41–47PubMedGoogle Scholar
  51. Fosella F, DeVore R, Kerr RN et al (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non small cell lung cancer previously treated with platinum containing chemotherapy regimens. J Clin Oncol 18:2354–2362Google Scholar
  52. Fossella FV (1999) Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials. Semin Oncol 26(suppl 16):17–23PubMedGoogle Scholar
  53. Fournel P, Robinet G, Thomas P et al (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d’Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95–01 Study. J Clin Oncol 23:5910–5917PubMedCrossRefGoogle Scholar
  54. Fournel P, Vergnene′ gre A, Robinet G et al (2006) Induction or consolidation chemotherapy with cisplatin (C) And paclitaxel (P) plus concurrent chemo-radiation with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer patients: randomized phase II trial GFPC-GLOT-IFCT 02-01. J Clin Oncol, ASCO Annual Meeting Proceedings Part I 24: 18S (June 20 Suppl), 7048, 2006 Google Scholar
  55. Furuse K, Fukuoka M, Kawahara M et al (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small cell lung cancer. J Clin Oncol 17:2692–2699PubMedGoogle Scholar
  56. Gadgeel S, Ruckdeschel J, Wozniak A et al (2008) Pemetrexed and cisplatin with concurrent thoracic radiation therapy (TRT) followed by docetaxel in stage III non-small cell lung cancer (NSCLC) patients (pts).In: ASCO Annual Meeting Proceedings. J Clin Oncol 26 (abstract 7569)Google Scholar
  57. Gandara DR, Chansky K, Albain KS et al (2003) Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 21:2004–2010PubMedCrossRefGoogle Scholar
  58. Gatzemeier U, Shepherd FA, Le Chevalier T et al (1996) Activity of gemcitabine in patients with non-small cell lung cancer: a multicentre, extended phase II study. Eur J Cancer 32:243–248aCrossRefGoogle Scholar
  59. Gauden S, Haug G, Markos J et al (2009) Phase II study of combined modality therapy with concurrent docetaxel and carboplatin plus radiation therapy followed by consolidation pemetrexed chemotherapy for unresectable stage III non-small-cell-lung cancer. IASCL 13th World Conference on Lung Cancer: P3.014 (abstract)Google Scholar
  60. Germonpre P, Janssens A, Galdermans D et al (2009) A randomized muticenter phase II study of concurrent pemetrexed and radiotherapy with induction or adjuvant cisplatin/pemetrexed in patients with unresectable stage III non-small cell lung cancer (NSCLC) IASLC 13th World Conference on Lung Cancer: P3.015 (abstract)Google Scholar
  61. Giaccone G, Splinter TA, Debruyne C et al (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer: The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16:2133–2141PubMedGoogle Scholar
  62. Ginsberg R, Vokes EE, Rosenzweig K (2001) Non-small cell lung cancer. In: DeVita JV, Hellman S, Rosenberg SA (eds) Cancer-Principles, Practice of Oncology, 6th edn. JB Lippinoctt Co, Philadelphia, PA, pp 925–982Google Scholar
  63. Govindan R, Bogart J, Wang X et al (2008) A phase II study of pemetrexed, carboplatin and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407–Early evaluation of feasibility and toxicity. J Clin Oncol 26(18 suppl):401s (Abstract 7518)Google Scholar
  64. Graham MV, Purdy JA, Emami B et al (1999) Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45:323–329PubMedCrossRefGoogle Scholar
  65. Gumerlock PH, Mack PC, Manorek GH et al (1999) Bcl-2 phosphorylation, p27 induction as potential p53-independent mechanisms of apoptotic response to taxanes in non-small cell lung carcinoma. Proc Am Assoc Cancer Res 40:739 (abstr 4879)Google Scholar
  66. Hanna N, Neubauer M, Yiannoutsos C et al (2008) Phase III trial of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III nonsmall- cell lung cancer: The Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 26:5755–5760PubMedCrossRefGoogle Scholar
  67. Hatcher N, Ranson M, Anderson H et al (1998) Phase III study of paclitaxel (Taxol) (T) versus best supportive care (BSC) in inoperable non-small cell lung cancer (NSCLC). Presented at the 23rd Congress of the European Society of Medical Oncology, Athens, GreeceGoogle Scholar
  68. Heinemann V, Hertel LW, Grindey GB et al (1988) Comparison of the cellular pharmacokinetics and toxicity of 2’, 2’- difluorodeoxycytidine and 1-beta-D-arabinofuranosylcytosine. Cancer Res 48:4024–4031PubMedGoogle Scholar
  69. Heinzerling J, Choy H, Hughes R et al (2010) Toxicity and response of pemetrexed plus carboplatin or cisplatin with concurrent chest radiation therapy for patients with locally advanced non-small cell lung cancer: a phase I trial. J Thorac Oncol 5:1391–1396CrossRefGoogle Scholar
  70. Hensing T, Patel J, Marymont M et al. (2009) A phase I trial of cisplatin, pemetrexed, and radiation in patients with stage III non-small-cell lung cancer. IASLC 13th World Conference on Lung Cancer:P3.019 (abstract)Google Scholar
  71. Hertel LW, Boder GB, Kroin JS et al (1990) Evaluation of the antitumor activity of gemcitabine (2’, 2’-difluoro-2’- deoxycytidine). Cancer Res 50:4417–4422PubMedGoogle Scholar
  72. Hirsh V, Soulieres D, Duclos M, Faria S, Del Vecchio P, Ofiara L, Ayoub JP, Charpentier D, Gruber J, Portelance L, Souhami L (2007) Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol 2(10):927–932PubMedCrossRefGoogle Scholar
  73. Hoffman PC, Mauer AM, Vokes EE (2000) Lung cancer. Lancet 355:479–485 (published erratum appears in Lancet 355:1280, 2000)PubMedGoogle Scholar
  74. Hsiang YH, Liu LF (1988) Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 48:1722–1726PubMedGoogle Scholar
  75. Hsiang YH, Hertzberg R, Hecht S et al (1985) Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 260:14873–14878PubMedGoogle Scholar
  76. Huber RM, Flentje M, Schmidt M, Pöllinger B, Gosse H, Willner J, Ulm K, Group Bronchial Carcinoma Therapy (2006) Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small-cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 24(27):4397–4404PubMedCrossRefGoogle Scholar
  77. Jain AK, Hughes RS, Sandler AB, Dowlati A, Schwartzberg LS, Dobbs T, Schlabach L, Wu J, Muldowney NJ, Choy H (2009) A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thoracic Oncol 4(6):722–727CrossRefGoogle Scholar
  78. Joerger M, Omlin A, Cerny T, Früh M (2010) The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets 11:37–47PubMedCrossRefGoogle Scholar
  79. Johnson DH (1999) Treatment strategies for metastatic non-small-cell lung cancer. Clin Lung Cancer 1:34–41PubMedCrossRefGoogle Scholar
  80. Johnson DH, Paul DM, Hande KR et al (1996) Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: A phase II trial. J Clin Oncol 14:2054–2060PubMedGoogle Scholar
  81. Kaplan B, Altýnbas M, Eroglu C, Karahacioglu E, Er O, Ozkan M, Bilgin M, Canoz O, Gulmez I, Gulec M (2004) Preliminary results of a phase II study of weekly paclitaxel (PTX) and carboplatin (CBDCA) administered concurrently with thoracic radiation therapy (TRT) followed by consolidation chemotherapy with PTX/CBDCA for stage III unresectable non-small-cell lung cancer (NSCLC). Am J Clin Oncol 27(6):603–610PubMedCrossRefGoogle Scholar
  82. Kelly K, Chansky K, Gaspar LE, Albain KS, Jett J, Ung YC, Lau DH, Crowley JJ, Gandara DR (2008) Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26(15):2450–2456PubMedCrossRefGoogle Scholar
  83. Kim S, Kim M, Choi E et al (2007) Induction chemotherapy followed by concurrent chemoradiotherapy (CCRT) versus CCRT alone for unresectable stage III non–small-cell lung cancer (NSCLC): Randomized phase III trial. J Clin Oncol 25:391s (suppl; abstr 7528)Google Scholar
  84. Klastersky J, Sculier JP, Lacroix H, Dabouis G, Bureau G, Libert P, Richez M, Ravez P, Vandermoten G, Thiriaux J et al (1990) A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. J Clin Oncol 8:1556–1562PubMedGoogle Scholar
  85. Komaki R, Seiferheld W, Curran W et al (2003) Sequential versus concurrent chemotherapy, radiation therapy for inoperable non-small cell lung cancer (NSCLC): analysis of failures in a phase III study (RTOG 9410). Int J Radiat Oncol Biol Phys 48:113CrossRefGoogle Scholar
  86. Kosmidis PA, Mylonakis N, Fountzilas G, Samantas E, Athanasiadis A, Andreopoulou E, Pavlidis N, Skarlos D (1997) Paclitaxel and carboplatin in inoperable non-small-cell lung cancer: a phase II study. Ann Oncol 8:697–699PubMedCrossRefGoogle Scholar
  87. Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, Henke M, Lopez M, Bell D, Biti G, Merimsky O, Beorchia A, Riggi M, Caux NR, Pouget JC, Dubray B, David P (2008) Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. J Thorac Oncol 3(9):994–1002PubMedCrossRefGoogle Scholar
  88. Kudoh S, Takada M, Masuda N et al (1993) Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84:203–207PubMedCrossRefGoogle Scholar
  89. Langer CJ, Leighton JC, Comis RL et al (1995) Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: A phase II toxicity, response, and survival analysis. J Clin Oncol 13:1860–1870PubMedGoogle Scholar
  90. Lau D, Leigh B, Gandara D (2001) Twice-weekly paclitaxel and weekly carboplatin with concurrent thoracic radiation followed by carboplatin/paclitaxel consolidation for Stage III non-small-cell lung cancer: a california cancer consortium phase II trial. J Clin Oncol 19:442–447PubMedGoogle Scholar
  91. Lawrence TS, Chang EY, Hahn TM et al (1996) Radiosensitization of pancreatic cancer cells by 2’, 2’-difluoro-2’-deoxycytidine. Int J Radiat Oncol Biol Phys 34:867–872PubMedCrossRefGoogle Scholar
  92. Le Chevalier T, Brisgand D, Douillard JY et al (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versusvinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12:360–367PubMedGoogle Scholar
  93. Lee JS, Scott C, Komaki R et al (1996) Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91–06. J Clin Oncol 14:1055–1064PubMedGoogle Scholar
  94. Lee CB, Stinchcombe TE, Rosenman JG et al (2006) Therapeutic advances in local-regional therapy for stage III non-small-cell lung cancer: evolving role of dose-escalated conformal (3-dimensional) radiation therapy. Clin Lung Cancer 8:195–202PubMedCrossRefGoogle Scholar
  95. Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ, Lee JS (2005) Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 63(4):1037–1044PubMedCrossRefGoogle Scholar
  96. Leong SS, Fong KW, Lim WT, Toh CK, Yap SP, Hee SW, Tan EH (2010) A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer 67(3):325–329PubMedCrossRefGoogle Scholar
  97. Machtay M, Werner-Wasik M, DeNittis A et al. (2008) Pilot study of carboplatin/radiotherapy plus ‘dose-dense’ pemetrexed for locally advanced non-small cell lung carcinoma. J Clin Oncol. ASCO Annual Meeting Proceedings 26 7571 (abstract), 2008Google Scholar
  98. Manfredi JJ, Parness J, Horwitz SB (1982) Taxol binds to cellular microtubules. J Cell Biol 94:688–696PubMedCrossRefGoogle Scholar
  99. Micetich KC, Barnes D, Ericson LC (1985) A comparative study of the cytotoxicity of anticancer platinum drugs: evidence that cis-diamminedichloroplatinum (II) and cis-diammine-(l.I-cyclobutanedicarboxylato) platinum (II) differ only in the kinetics of their interaction with DNA. Cancer Res 45:4043–4047PubMedGoogle Scholar
  100. Movsas B, Langer CJ, Ross HJ, Wang L, Jotte RM, Feigenberg S, Xu F, Huang CH, Monberg MJ, Obasaju CK (2010) Randomized phase II trial of cisplatin, etoposide, and radiation followed by gemcitabine alone or by combined gemcitabine and docetaxel in stage III A/B unresectable non-small cell lung cancer. J Thorac Oncol 5(5):673–679PubMedGoogle Scholar
  101. Movsas B, Scott C, Sause W et al (1999) The benefit of treatment intensification is age and histology-dependent in patients with locally advanced non-small cell lung cancer (NSCLC): a quality-adjusted survival analysis of radiation therapy oncology group (RTOG) chemoradiation studies. Int J Radiat Oncol Biol Phys 45:1143–1149PubMedCrossRefGoogle Scholar
  102. Movsas B et al (2003) Phase III study of amifostine in patients with locally advanced non-small cell lung cancer (NSCLC) receiving chemotherapy & hyperfractionated radiation: Radiation Therapy Oncology Group (RTOG) 98–01. Pro Amer Soc Clin Oncol 22:636Google Scholar
  103. Nakamura H, Yamaji Y, Fujita T et al (1995) Synergistic growth inhibition of gemcitabine/cisplatin, gemcitabine/etoposide on a human lung cancer cell line, RERFLC-OK. Proc Am Assoc Cancer Res 36:A2425Google Scholar
  104. Nitiss J, Wang JC (1988) DNA topoisomerase-targeting antitumor drugs can be studied in yeast. Proc Natl Acad Sci U S A 85:7501–7505PubMedCrossRefGoogle Scholar
  105. Non-Small-Cell Lung Cancer Collaborative Group (1995) Chemother- apy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311:899–909CrossRefGoogle Scholar
  106. Omura M, Torigoe S, Kubota N (1997) SN-38, a metabolite of the camptothecin derivative CPT-11, potentiates the cytotoxic effect of radiation in human colon adenocarcinoma cells grown as spheroids. Radiother Oncol 43:197–201PubMedCrossRefGoogle Scholar
  107. Parness J, Horwitz SB (1981) Taxol binds to polymerized tubulin in vitro. J Cell Biol 91:479–487PubMedCrossRefGoogle Scholar
  108. Patel SH, Ajlouni M, Chapman R, Lu M, Movsas B, Kim JH (2007) A prospective phase II study of induction carboplatin and vinorelbine followed by concomitant topotecan and accelerated radiotherapy (ART) in locally advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2(9):831–837PubMedCrossRefGoogle Scholar
  109. Perez CA, Stanley K, Grundy G et al (1982) Impact of irradiation technique and tumor extent in tumor control and survival of patients with unresectable non-oat cell carcinoma of the lung: report by The Radiation Therapy Oncology Group. Cancer 50:1091–1099PubMedCrossRefGoogle Scholar
  110. Perez CA, Pajak TF, Rubin P et al (1987) Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy: report by The Radiation Therapy Oncology Group. Cancer 59:1874–1881PubMedCrossRefGoogle Scholar
  111. Perol M, Guérin JC, Thomas P et al (1996) Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycinvindesine in advanced non-small cell lung cancer. Lung Cancer 14:119–134PubMedCrossRefGoogle Scholar
  112. Peterson P, Park K, Fossella F et al (2007) Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed versus docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC) 12th World Conference on Lung Cancer. J Thorac Oncol 2(suppl 4):S851 (Abstract P2-328)CrossRefGoogle Scholar
  113. Ratanatharathorn V, Lorvidhaya V, Maoleekoonpairoj S, Phromratanapongse P, Sirilerttrakul S, Kraipiboon P, Cheirsilpa A, Tangkaratt S, Srimuninnimit V, Pattaranutaporn P (2001) Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Lung Cancer 31:257–265PubMedCrossRefGoogle Scholar
  114. Radiation Therapy Oncology Group. RTOG 0617/NCCTG N0628/CALGB 30609 A randomzed phase III comparison of standard-dose (60 Gy) versus high dose (74 Gy) conformal radiotherapy with concurrent and consolidation carboplatin/paclitaxel in patients with stage IIIA/IIIB non-small cell lung cancer. http://www.rtog.org/members/protocols/0617/0617.pdf. Accessed 11 Mar 2011
  115. Reguart N, Viñolas N, Casas F, Gimferrer JM, Agustí C, Molina R, Martin-Richard M, Sanchez-Reyes A, Gascón P (2004) Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results. Lung Cancer 45(1):67–75Google Scholar
  116. Rich TA, Kirichenko AV (1998) Camptothecin radiation sensitization: mechanisms, schedules, and timing. Oncology (Huntingt) 12(suppl 6):114–120Google Scholar
  117. Rosenman JG, Halle JS, Socinski MA et al (2002) High-dose conformal radiotherapy for treatment of stage IIIA/IIIB non-small-cell lung cancer: technical issues and results of a phase I/II trial. Int J Radiat Oncol Biol Phys 54:348–356PubMedCrossRefGoogle Scholar
  118. Rowinsky EK, Donehower RC (1995) Paclitaxel (taxol). N Engl J Med 332:1004–1014PubMedCrossRefGoogle Scholar
  119. Rowinsky EK, Chaudhry V, Forastiere AA, Sartorius SE, Ettinger DS, Grochow LB, Lubejko BG, Cornblath DR, Donehower RC (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol 11:2010–2020PubMedGoogle Scholar
  120. Rusthoven J, Eisenhauer E, Butts C et al (1999) Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced nonsmall cell lung cancer: a phase II study—National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 17:1194–1199PubMedGoogle Scholar
  121. Rusu P, Ciuleanu TE, Cernea D, Pelau D, Gaal V, Cebotaru C, Guttman T, Todor N, Ghilezan N (2007) Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study. J BUON 12(1):33–39Google Scholar
  122. Saka H, Shimokata K, Yoshida S et al (1997) Irinotecan (CPT-11) and concurrent radiotherapy in locally advanced non-small cell lung cancer (NSCLC): a phase II study of Japan Clinical Oncology Group (JCOG9504). Proc Am Soc Clin Oncol 16:447a (Abstract 1607)Google Scholar
  123. Sakai H, Yoneda S, Kobayashi K, Komagata H, Kosaihira S, Kazumoto T, Saito Y (2004) Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer. Lung Cancer 43(2):195–201PubMedCrossRefGoogle Scholar
  124. Sandler AB, Nemunaitis J, Denham C et al (2000) Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18:122–130PubMedGoogle Scholar
  125. Sause WT, Scott C, Taylor S et al (1995) Radiation Therapy Oncology Group (RTOG) 88–08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced unresectable non-small-cell lung cancer. J Natl Cancer Inst 87:198–205PubMedCrossRefGoogle Scholar
  126. Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551PubMedCrossRefGoogle Scholar
  127. Schaake-Koning C, Van Den Bogaert W, Dalesio O et al (1992) Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. N Engl J Med 326:521–530CrossRefGoogle Scholar
  128. Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by Taxol. Nature 22:665–667CrossRefGoogle Scholar
  129. Schild SE, McGinnis WL, Graham D et al (2006) Results of a phase I trial of concurrent chemotherapy and escalating doses of radiation for unrespectable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 65:1106–1111PubMedCrossRefGoogle Scholar
  130. Seiwert T, Connell PP, Mauer AM et al (2007) A phase I study of pemetrexed, carboplatin, and concurrent radiotherapy in patients with locally advanced or metastatic nonsmall cell lung cancer or esophageal cancer. Clin Cancer Res 13:515–522PubMedCrossRefGoogle Scholar
  131. Segawa Y, Kiura K, Takigawa N, Kamei H, Harita S, Hiraki S, Watanabe Y, Sugimoto K, Shibayama T, Yonei T, Ueoka H, Takemoto M, Kanazawa S, Takata I, Nogami N, Hotta K, Hiraki A, Tabata M, Matsuo K, Tanimoto M (2010) Phase III trial comparing docetaxel and cisplatin combination chemotherapy with mitomycin, vindesine, and cisplatin combination chemotherapy with concurrent thoracic radiotherapy in locally advanced non-small-cell lung cancer: OLCSG 0007. J Clin Oncol 28(20):3299–3306PubMedCrossRefGoogle Scholar
  132. Senan S, Cardenal F, Vansteenkiste J, Stigt J, Akyol F, De Neve W, Bakker J, Dupont JM, Scagliotti GV, Ricardi U, van Meerbeeck JP (2011) A randomized phase II study comparing induction or consolidation chemotherapy with cisplatin-docetaxel, plus radical concurrent chemoradiotherapy with cisplatin-docetaxel, in patients with unresectable locally advanced non-small-cell lung cancer. Ann Oncol 22(3):553–558PubMedCrossRefGoogle Scholar
  133. Shewach DS, Hahn TM, Chang E et al (1994) Metabolism of 2’, 2’-difluoro-2’-deoxycytidine and radiation sensitization of human colon carcinoma cells. Cancer Res 54:3218–3223PubMedGoogle Scholar
  134. Sinclair WK, Morton RA (1966) X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat Res 29:450–474PubMedCrossRefGoogle Scholar
  135. Smit E, Mattson K, von Pawel J et al (2003) ALIMTA (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: a phase II study. Ann Oncol 14:455–460PubMedCrossRefGoogle Scholar
  136. Socinski MA, Rosenman JG, Halle JS et al (2000) Induction carboplatin/paclitaxel followed by concurrent carboplatin/paclitaxel and dose-escalating conformal thoracic radiation therapy in unresectable stage IIIA/B non-small cell lung cancer: a modified phase I trial. Cancer 89:534–542PubMedCrossRefGoogle Scholar
  137. Socinski MA, Blackstock AW, Bogart JA et al (2008) Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 26:2457–2463PubMedCrossRefGoogle Scholar
  138. Solomon B, Bunn PA Jr (2005) Clinical activity of pemetrexed: amultitargeted antifo- late anticancer agent. Future Oncol 1:733–746PubMedCrossRefGoogle Scholar
  139. Solomon B, Ball DL, Richardson G, Smith JG, Millward M, MacManus M, Michael M, Wirth A, O’Kane C, Muceniekas L, Ryan G, Rischin D (2003) Phase I/II study of concurrent twice-weekly paclitaxel and weekly cisplatin with radiation therapy for stage III non-small cell lung cancer. Lung Cancer 41(3):353–361PubMedCrossRefGoogle Scholar
  140. Stern A, Sevin BU, Perras J et al (1993) Taxol sensitizes human ovarian cancer cells to radiation. Cancer Res 48:252–258Google Scholar
  141. Takeda K, Negoro S, Kudoh S et al (1999) Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 79:1462–1467PubMedCrossRefGoogle Scholar
  142. Tanzer LR, Rutherford PG, Self TD et al (1995) Antitumor activity of gemcitabine in combination with cisplatin against the human NSCLC xenograft Calu-6. Proc Am Assoc Cancer Res 36:A1761Google Scholar
  143. Tishler RB, Geard CR, Hall EJ et al (1992a) Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 51:3459–3497Google Scholar
  144. Tishler RB, Schiff PB, Geard CR et al (1992b) Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22:613–617PubMedCrossRefGoogle Scholar
  145. Uejima H (2002) Dose-finding study of weekly irinotecan (CPT-11) and carboplatin (CBDCA) with concurrent thoracic radiotherapy (TRT) in locally advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 20:A–A2699Google Scholar
  146. Vafai D, Israel V, Zaretsky S et al (1995) Phase II trial of combination carboplatin and taxol in non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 14:352 (abstr 1067)Google Scholar
  147. Vergnenègre A, Daniel C, Léna H, Fournel P, Kleisbauer JP, Le Caer H, Letreut J, Paillotin D, Pérol M, Bouchaert E, Preux PM, Robinet G, Groupe Francais de Pneumo-Cancerologie (2005) Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC). Lung Cancer 47(3):395–404PubMedCrossRefGoogle Scholar
  148. Vokes EE, Herndon JE 2nd, Crawford J et al (2002) Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20:4191–4198PubMedCrossRefGoogle Scholar
  149. Vokes EE, Herndon JE II, Kelley MJ et al (2007) Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non–small-cell lung cancer: Cancer and leukemia group B. J Clin Oncol 25:1698–1704PubMedCrossRefGoogle Scholar
  150. Vokes EE, Senan S, Treat JA et al (2009) PROCLAIM: a phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non small-cell lung cancer of other than predominantly squamous cell histology. Clin Lung Cancer 10:193–198PubMedCrossRefGoogle Scholar
  151. Wasserman T, Chapman JD (2004) Radiation response modulation. Part A: chemical sensitizers and protectors. In: Perez C, Brady L, Halperin E et al (eds) Principles, practice of radiation oncology, 4th edn. JB Lippincott, Philadelphia, PAGoogle Scholar
  152. Wozniak AJ, Crowley JJ, Balcerzak SP et al (1998) Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study. J Clin Oncol 16:2459–2465PubMedGoogle Scholar
  153. Xu Y, Ma S, Ji Y et al (2010) Concomitant chemoradiotherapy using pemetrexed and carboplatin for unresectable stage III non-small cell lung cancer (NSCLC): Preliminary results of a phase II study. Lung Cancer. (Epub ahead of print)Google Scholar
  154. Yamada M, Kudoh S, Fukuda H et al (2002) Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unrespectable stage III non-small cell lung cancer. Br J Cancer 87:258–263PubMedCrossRefGoogle Scholar
  155. Yamamoto N, Nakagawa K, Nishimura Y et al (2010) Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 28:3739–3745PubMedCrossRefGoogle Scholar
  156. Zatloukal P et al (2004) Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46(1):87–98PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2011

Authors and Affiliations

  1. 1.Department of Radiation OncologyUT Southwestern Medical Center at DallasDallasUSA

Personalised recommendations